Features
Launching into a crowded therapeutic category: sequencing market access, medical affairs, and commercial
Successful drug launches in crowded markets depend on sequencing, not marketing.
By Marcus Thibodeau
Wednesday, August 5, 2026Features
Features
HCP engagement after the rep: what field teams and digital channels each still do better
Field reps and digital channels excel at different things; deploy both strategically.
Features
Modular content in pharma marketing: what breaks when you try to reuse approved claims across channels
Reusing approved claims across channels requires more scrutiny than most teams provide.
Features
What actually slows down MLR review, and why adding more reviewers rarely fixes it
Slow MLR review stems from poor submissions, not reviewer shortage.
Features
HCP engagement after the rep: what field teams and digital channels each still do better
Field reps and digital channels excel at different things; deploy both strategically.
Modular content in pharma marketing: what breaks when you try to reuse approved claims across channels
Reusing approved claims across channels requires more scrutiny than most teams provide.
What actually slows down MLR review, and why adding more reviewers rarely fixes it
Slow MLR review stems from poor submissions, not reviewer shortage.